Echocardiographic Evaluation of Left Atrial Function to Discriminate Non-Valvular Atrial Fibrillation Development in Patients with Apical Hypertrophic Cardiomyopathy.
Apical hypertrophic cardiomyopathy
Atrial fibrillation
Speckle tracking
Strain imaging
Journal
Acta Cardiologica Sinica
ISSN: 1011-6842
Titre abrégé: Acta Cardiol Sin
Pays: China (Republic : 1949- )
ID NLM: 101687085
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
entrez:
7
1
2020
pubmed:
7
1
2020
medline:
7
1
2020
Statut:
ppublish
Résumé
Data is limited on baseline left atrial (LA) myocardial mechanics between apical hypertrophic cardiomyopathy (ApHCM) patients who develop non-valvular atrial fibrillation (NVAF) during follow-up and those who do not. This retrospective study investigated the clinical outcomes of consecutive patients newly diagnosed with ApHCM between August 2011 and July 2014 who were followed-up for at least 3 years. The patients underwent 12-lead surface electrocardiography and/or 24-hour Holter electrocardiography at least once a year. The patients were divided into two groups, namely those who did or did not exhibit NVAF during follow-up, respectively. The baseline clinical and echocardiographic data of the two groups were compared. Twenty patients were studied, five of whom were lost to follow-up. Of the remaining 15 ApHCM patients, seven developed NVAF. No differences were observed in the clinical characteristics of the two groups. However, for the echocardiographic data, the NVAF development group exhibited a larger LA volume and impaired LA reservoir, conduit and booster functions. The NVAF development group also showed lower peak LA strain and stiffer left atrium. The LA volume, function, global strain and stiffness were all statistically associated with NVAF development. Among these parameters, a LA conduit function of ≤ 24.9% was found to be the best parameter to discriminate NVAF development. The baseline LA function was impaired in the ApHCM patients who subsequently developed NVAF during follow-up. A LA conduit function of ≤ 24.9% was strongly associated with NVAF development.
Sections du résumé
BACKGROUND
BACKGROUND
Data is limited on baseline left atrial (LA) myocardial mechanics between apical hypertrophic cardiomyopathy (ApHCM) patients who develop non-valvular atrial fibrillation (NVAF) during follow-up and those who do not.
METHODS
METHODS
This retrospective study investigated the clinical outcomes of consecutive patients newly diagnosed with ApHCM between August 2011 and July 2014 who were followed-up for at least 3 years. The patients underwent 12-lead surface electrocardiography and/or 24-hour Holter electrocardiography at least once a year. The patients were divided into two groups, namely those who did or did not exhibit NVAF during follow-up, respectively. The baseline clinical and echocardiographic data of the two groups were compared.
RESULTS
RESULTS
Twenty patients were studied, five of whom were lost to follow-up. Of the remaining 15 ApHCM patients, seven developed NVAF. No differences were observed in the clinical characteristics of the two groups. However, for the echocardiographic data, the NVAF development group exhibited a larger LA volume and impaired LA reservoir, conduit and booster functions. The NVAF development group also showed lower peak LA strain and stiffer left atrium. The LA volume, function, global strain and stiffness were all statistically associated with NVAF development. Among these parameters, a LA conduit function of ≤ 24.9% was found to be the best parameter to discriminate NVAF development.
CONCLUSIONS
CONCLUSIONS
The baseline LA function was impaired in the ApHCM patients who subsequently developed NVAF during follow-up. A LA conduit function of ≤ 24.9% was strongly associated with NVAF development.
Identifiants
pubmed: 31903006
doi: 10.6515/ACS.202001_36(1).20190704B
pmc: PMC6933495
doi:
Types de publication
Journal Article
Langues
eng
Pagination
33-43Références
Am Heart J. 1993 Jun;125(6):1814-5
pubmed: 8498342
Cardiovasc Ultrasound. 2013 Nov 14;11:40
pubmed: 24229344
Cardiovasc Ultrasound. 2011 Nov 18;9:34
pubmed: 22099329
Am J Cardiol. 2003 Mar 15;91(6):780-4
pubmed: 12633827
Eur J Echocardiogr. 2011 Mar;12(3):167-205
pubmed: 21385887
J Am Coll Cardiol. 2011 Jul 26;58(5):493-501
pubmed: 21777747
Eur Heart J Cardiovasc Imaging. 2016 Jun;17(6):678-86
pubmed: 26245912
J Cardiovasc Ultrasound. 2012 Sep;20(3):140-5
pubmed: 23185657
Am J Cardiol. 2001 Oct 15;88(8):927-32, A9
pubmed: 11676968
Eur Heart J. 2007 Nov;28(22):2738-48
pubmed: 17959621
J Interv Card Electrophysiol. 2009 Nov;26(2):127-32
pubmed: 19529886
J Nephrol. 2012 Jan-Feb;25(1):96-106
pubmed: 21607916
J Am Soc Echocardiogr. 2010 Sep;23(9):961-7
pubmed: 20667694
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
J Formos Med Assoc. 2016 Nov;115(11):893-952
pubmed: 27890386
Jpn Heart J. 1976 Sep;17(5):611-29
pubmed: 136532
Int J Cardiol. 2010 Mar 4;139(2):173-80
pubmed: 19046608
Eur J Echocardiogr. 2011 Jun;12(6):421-30
pubmed: 21565866
Cardiology. 2006;106(1):29-35
pubmed: 16612066
J Am Soc Echocardiogr. 2015 Jun;28(6):709-17
pubmed: 25704553
J Am Coll Cardiol. 2006 Mar 7;47(5):1018-23
pubmed: 16516087
Circ Cardiovasc Imaging. 2009 Jan;2(1):10-5
pubmed: 19808559
Acta Cardiol Sin. 2018 Jul;34(4):344-351
pubmed: 30065573
J Am Soc Echocardiogr. 2011 Aug;24(8):898-908
pubmed: 21665431
J Cardiol. 2017 May;69(5):731-738
pubmed: 27567175
J Am Soc Echocardiogr. 2010 Feb;23(2):172-80
pubmed: 20152699
Eur Heart J Cardiovasc Imaging. 2016 Dec;17(12):1321-1360
pubmed: 27422899
Am J Cardiol. 1999 Oct 1;84(7):829-32
pubmed: 10513783
Circulation. 1997 Oct 7;96(7):2455-61
pubmed: 9337224
J Am Soc Echocardiogr. 2011 May;24(5):513-9
pubmed: 21353469
Acta Cardiol Sin. 2017 Jan;33(1):50-57
pubmed: 28115807
Heart. 2017 Oct;103(19):1496-1501
pubmed: 28428444
Heart Rhythm. 2011 Sep;8(9):1364-71
pubmed: 21354332
Heart. 2011 Nov;97(22):1847-51
pubmed: 21357370
J Am Coll Cardiol. 2008 Feb 26;51(8):802-9
pubmed: 18294563
J Am Coll Cardiol. 2002 Feb 20;39(4):638-45
pubmed: 11849863
Stroke. 2000 Nov;31(11):2616-22
pubmed: 11062284